Back to Search
Start Over
Promising therapy for neuroendocrine prostate cancer: current status and future directions.
- Source :
-
Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2024 Aug 08; Vol. 16, pp. 17588359241269676. Date of Electronic Publication: 2024 Aug 08 (Print Publication: 2024). - Publication Year :
- 2024
-
Abstract
- Neuroendocrine prostate cancer (NEPC) is a highly aggressive variant of castration-resistant prostate cancer. It is characterized by low or no expression of the androgen receptor (AR), activation of AR-independent signaling, and increased neuroendocrine phenotype. Most of NEPC is induced by treatment of androgen deprivation therapy and androgen receptor pathway inhibitors (ARPIs). Currently, the treatment of NEPC follows the treatment strategy for small-cell lung cancer, lacking effective drugs and specific treatment options. This review summarizes potential novel targets and therapies for NEPC treatment, including epigenetic regulators (zeste homolog 2 inhibitors, lysine-specific demethylase 1 inhibitors), aurora kinase A inhibitors, poly-ADP-ribose polymerase inhibitors, delta-like ligand 3 targeted therapies, a combination of immunotherapies, etc. Other promising targets and future directions are also discussed in this review. These novel targets and therapies may provide new opportunities for the treatment of NEPC.<br />Competing Interests: The authors declare that there is no conflict of interest.<br /> (© The Author(s), 2024.)
Details
- Language :
- English
- ISSN :
- 1758-8340
- Volume :
- 16
- Database :
- MEDLINE
- Journal :
- Therapeutic advances in medical oncology
- Publication Type :
- Academic Journal
- Accession number :
- 39131727
- Full Text :
- https://doi.org/10.1177/17588359241269676